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The effect of istradefylline for 
Parkinson’s disease: A meta-
analysis
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Adenosine A2A receptor antagonists are an alternative treatment strategy for Parkinson’s disease. 
Several randomized placebo controlled studies have tested the effect of A2A receptor antagonist 
istradefylline, and more robust evidence has been acquired. This meta-analysis aimed to provide 
evidence for its efficacy and safety on patients with Parkinson’s disease. After a systematic literature 
search, we calculated the pooled standardized mean difference and risk ratio for continuous and 
dichotomous variables, respectively. Further, sensitivity analyses were performed to confirm the effect 
estimated by meta-analyses. Publication bias was assessed by funnel plot and deviation of intercept. 
Six studies satisfied our inclusion criteria. Istradefylline (40 mg/day) decreased off time and improved 
motor symptoms of Parkinson’s disease in homogeneous studies. Istradefylline at 20 mg/day decreased 
off time and improved motor symptoms, but heterogeneity was found in the analysis of the former 
among studies. There was a significant effect of istradefylline on dyskinesia in homogeneous studies. 
Publication bias, however, was observed in the comparison of dyskinesia. Other adverse events 
showed no significant difference. The present meta-analysis suggests that istradefylline at 40 mg/day 
could alleviate off time and motor symptoms derived from Parkinson’s disease. Dyskinesia might be 
worsened, but publication bias prevents this from being clear.
Parkinson’s disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra pars 
compacta (SNc), which induces motor symptoms including tremor, rigidity, akinesia, bradykinesia, and postural 
instability. A reduced concentration of dopamine in the striatum induces hyperactivation of the globus pallidus 
internus via inhibition of the direct pathway and excitation of the indirect pathway. The motor output from the 
striatum is considered to consist of direct and indirect pathways1, which mainly express dopamine D1 and D2 
receptors, respectively. Recent transgenic mouse models have allowed for confirmation of the existence of two 
distinct pathways2,3.
Patients with PD are usually treated with dopamine-related drugs including levodopa, monoamine oxidase 
B inhibitors and dopamine agonists, which in turn increase the risk of motor and non-motor complications4–7. 
Non-dopaminergic agents are thus needed for improving PD therapy and limiting side effects. Caffeine, a 
non-specific adenosine A2A receptor antagonist, could reduce the risk of the onset of PD and subsequent dyskine-
sia caused by long-term dopaminergic drug therapy8–10. In this context, the A2A receptor antagonist istradefylline 
was originally developed to address motor and non-motor complications related to advanced use of dopaminer-
gic drugs.
The effect of istradefylline was tested in several randomized placebo-controlled studies11–17, and was validated 
by other meta-analyses18,19. However, previous meta-analyses calculated a summary effect using the mean differ-
ence without standardization, although different estimators and subjects were involved in each study. In addition, 
an assessment of tolerability and publication bias and sensitivity analyses, were not performed. Furthermore, the 
first published meta-analysis estimated a summary effect using only three studies for each dosage, and excluded 
the work of Stacy et al.17 in the analysis of the effect of istradefylline (20 mg/day) on off time18. The second pub-
lished meta-analysis combined all studies regardless of dosage, and did not assess adverse events19. To more 
robustly analyze the evidence for use of istradefylline, a detailed and systematic meta-analysis was performed.
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Methods
The general methodology is comparable to our previously published meta-analyses20,21.
Study Selection. Inclusion criteria in the present meta-analysis comprised the following: (1) 20 mg/day or 
40 mg/day istradefylline use for PD; (2) placebo-controlled randomized trial with more than 10 subjects in each 
group; (3) assessment of off time or unified Parkinson’s disease rating scale (UPDRS) III during the on period; 
(4) written in English. A systematic literature search of PubMed, Web of Science and Cochrane Library was 
performed in May 2016 using the following syntax: (“Parkinson’s disease” or “PD”) and (“Istradefylline”) and 
(“randomized,” “random,” or “randomly”). As indicated in Fig. 1, six studies were finally included in the present 
meta-analysis. We contacted the corresponding author if incomplete data were detected. Three researchers inde-
pendently performed the above-mentioned search and study selection. Finally, we resolved any discrepancies 
after discussion. Risk of bias was evaluated by the Cochrane Collaboration’s tool for risk of bias.
Data Synthesis and Statistics. Detailed analysis methods are described in our previously published 
meta-analysis20. Briefly, we used the standardized mean difference (SMD) between the istradefylline and placebo 
groups, considering off time, UPDRS III score during the on phase, and UPDRS II score, to assess the effect of 
istradefylline 12 weeks after treatment. We estimated standard deviation (SD) for change from baseline based 
on a 95% confidence interval (CIs). In contrast to continuous data, a pooled risk ratio (RR) along with 95% 
CIs was calculated for dichotomous data. We investigated heterogeneity of the included studies with I-squared 
(I2). Adverse events described in more than 3 papers were defined as the targeted event. Sensitivity analyses 
were performed to establish robust evidence if there was a significant difference. All analyses were performed 
using Review Manager (RevMan 5.2) for Windows (http://ims.cochrane.org/revman) and R software (http://
www.r-project.org/).
Publication bias. In case of significant differences, publication bias was assessed by visual inspection and 
Egger’s test as described previously22.
Results
Study Characteristics and Risk of bias. Six placebo-controlled randomized studies met our inclusion 
criteria (n = 1175 istradefylline subjects, and n = 643 placebo subjects). The summary of the included studies is 
shown in supporting Table 1.
In terms of risk of bias, we cannot exclude the possibility of selection bias in several studies owing to a lack of 
description (please see supporting Fig. 1).
Figure 1. Flow chart of the inclusion process for the present meta-analysis.
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Off time and UPDRS III. For off time, the patients on 20 mg/day istradefylline showed significant improve-
ment across heterogeneous studies (SMD = −0.23, 95% confidence interval (CI) = −0.40 to −0.06, P = 0.009, 
I2 = 55%, Fig. 2A). This heterogeneity disappeared when “Pourcher 2012” was excluded (I2 = 0%, Fig. 2B). In con-
trast, at 40 mg/day, istradefylline reduced off time across homogeneous studies (SMD = −0.28, 95% CI = −0.44 
to −0.12, P = 0.0005, I2 = 34%, Fig. 2A). The significant effect of 20 mg/day istradefylline was lost without 
“Mizuno 2010” or “Mizuno 2013” (P = 0.06, supporting Table 2), but that of 40 mg/day was observed regardless 
of any exclusions (“LeWitt 2008,” P = 0.009; “Mizuno 2010,” P = 0.01; “Mizuno 2013,” P = 0.01; “Pourcher 2012,” 
P < 0.00001; supporting Table 2).
Istradefylline improved UPDRS III at on phase regardless of daily dose (20 mg, SMD = −0.15, 95% CI = −0.27 
to −0.02, P = 0.02; 40 mg, SMD = −0.24, 95% CI = −0.37 to −0.11, P = 0.0002; Fig. 3A). These studies were 
homogeneous (I2 = 0%, Fig. 3A). Furthermore, sensitivity analysis revealed a robust effect of 40 mg/day istrade-
fylline (“LeWitt 2008,” P < 0.0001; “Mizuno 2010,” P = 0.008; “Mizuno 2013,” P = 0.01; “Pourcher 2012,” P = 0.01; 
supporting Table 2). In contrast, there was no significant effect of istradefylline 20 mg/day without “Hauser 2008,” 
“Mizuno 2010,” or “Mizuno 2013” (“Hauser 2008,” P = 0.09; “Mizuno 2010,” P = 0.17; “Mizuno 2013,” P = 0.11; 
supporting Table 2).
No subgroup difference in off time or UPDRS III was seen between 20 mg/day and 40 mg/day istradefylline, 
which suggested that there was no dose effect (off time, I2 = 0%, Fig. 2A; UPDRS III, I2 = 2.0%; Fig. 3A).
Figure 2. Forest plots of the standardized mean difference in off time. (A) Istradefylline 40 mg/day showed 
a significant reduction of off time in homogeneous studies. In contrast, istradefylline 20 mg/day showed a 
significant reduction of off time in heterogeneous studies. (B) Heterogeneity disappeared in istradefylline 
20 mg/day use without “Pourcher 2012.”
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Tolerability. No significant difference was found between istradefylline and placebo groups in regard to 
dropouts (20 mg/day, P = 0.98; 40 mg/day, P = 0.99; Fig. 3B).
UPDRS II. Istradefylline did not improve UPDRS II scores at any daily doses (20 mg, P = 0.64; 40 mg, P = 0.44; 
please see supporting Fig. 2).
Adverse Events. Eight adverse events which satisfied our inclusion criteria were detected as targets. The 
aggravation of dyskinesia occurred more frequently in the istradefylline group than the placebo group (RR = 1.72, 
95% CI = 1.26 to 2.34, P = 0.0007, Fig. 4A). The included studies were homogeneous (I2 = 29%, Fig. 4A). A sig-
nificant effect of istradefylline was observed regardless of any exclusion (“Hauser 2008,” P = 0.005; “LeWitt 
2008,” P < 0.006; “Mizuno 2010,” P = 0.002; “Mizuno 2013,” P = 0.002; “Pourcher 2012,” P < 0.0001; “Stacy 2008,” 
P = 0.004; supporting Table 2). The other motor symptom, tremor, showed no significant difference between 
istradefylline and placebo groups (RR = 0.81, 95% CI = 0.23 to 2.87, P = 0.75, Fig. 4B). There was no signifi-
cant effect of istradefylline on the other adverse events (nausea, P = 0.41; constipation, P = 0.14; hallucination, 
P = 0.12; insomnia, P = 0.81; somnolence, P = 0.94; accident, P = 0.28, please see supporting Fig. 3).
Figure 3. Forest plots of the standardized mean difference in unified Parkinson’s disease rating scale III 
(UPDRS III) and the pooled risk ratio of dropout. (A) Istradefylline improved UPDRS III regardless of any 
dosage in homogeneous studies. (B) There was no significant difference of the incidence of dropout between 
placebo and istradefylline. The included studies were homogeneous.
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Publication bias. No clear asymmetry of funnel plots was identified, and there were no significant devia-
tions of intercept in all outcomes except for dyskinesia (off time 20 mg/day, P = 0.12; off time 40 mg/day, P = 0.19; 
UPDRS III 20 mg/day, P = 0.16; UPDRS III 40 mg/day, P = 0.34). For dyskinesia, the funnel plot appeared asym-
metrical (dyskinesia, P = 0.007, please see supporting Fig. 4).
Discussion
Our meta-analysis revealed that 40 mg/day istradefylline could improve off time and motor symptoms, and both 
findings were supported by a sensitivity analysis. In terms of the effect of 20 mg/day istradefylline on off time, 
however, heterogeneity of the included studies was detected, but its cause remained unknown. Furthermore, 
we failed to provide robust evidence for 20 mg/day istradefylline for off time or UPDRS III using a sensitivity 
analysis. It was noted that “Pourcher 2012” contributed to significant heterogeneity for the effect of 20 mg/day 
istradefylline on off time. The characteristics of “Pourcher 2012” related to this included increased dosage of 
daily levodopa intake with a wider range, more men, and a longer duration compared to the other studies, which 
suggests that they analyzed effects in a more advanced stage of PD. These factors could thus affect the results. 
Taken together, istradefylline could be recommended for use in the early stages of PD. Given the results of the 
sensitivity analyses, it was possible that the effect of 20 mg/day istradefylline was smaller than that of 40 mg/day. 
In such a case, istradefylline at 20 mg/day produced variable results owing to the different background of each 
study, whereas istradefylline at 40 mg/day stably improved off time and motor symptoms. However, considering 
significant but weak effect on these symptoms, istradefylline appeared suitable for adjuvant therapy at advanced 
stage in clinical practice.
Istradefylline was also administered at the advanced stage when dyskinesia was seen as motor complication 
owing to levodopa treatment. PD patients with levodopa-induced dyskinesia were reported to show elevated A2A 
receptor binding23. Given this finding, A2A receptor antagonists would be expected not to worsen dyskinesia. 
However, the exaggeration of dyskinesia was demonstrated by our meta-analysis; at the same time, publication 
bias could have contributed to this effect. Additional studies need to be performed to confirm the effect of istra-
defylline on levodopa-induced dyskinesia. There was no difference of the proportion of dropouts between istra-
defylline and placebo groups, which might indicate adequate tolerability in spite of the aggravation of dyskinesia.
No non-motor symptoms were worsened by istradefylline as in supporting Fig. 3. Administration of istra-
defylline was reported to improve overactive bladder and daytime sleepiness24,25, however, these were not 
randomized placebo-controlled trials. Further studies are needed to establish robust evidence of efficacy of istra-
defylline on non-motor symptoms.
A previous meta-analysis reported that coffee could reduce the risk of PD9. Caffeine is considered a nonspe-
cific A2A receptor antagonist8, and istradefylline is expected to have a similar effect to caffeine on neurons, i.e. 
a neuroprotective effect. Indeed, several papers demonstrated that A2A receptor antagonists prevented neuro-
degeneration in dopaminergic neurons in MPTP and 6-OHDA rodent models of PD26,27. Deletion of the A2A 
receptor inhibited loss of dopamine in the striatum, and of dopaminergic neurons in the SNc8. Furthermore, 
there was a tendency for caffeine to reduce the risk of developing dyskinesia in an observational study10. In this 
Figure 4. Forest plots of the pooled risk ratio of dyskinesia and tremor. (A) Homogeneous studies revealed that 
dyskinesia was worsened by istradefylline. (B) No significant difference was observed between groups for tremor.
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sense, istradefylline could be recommended for use before onset of dyskinesia or wearing off, to promote disease 
modification owing to neuroprotection of dopaminergic neurons; this is the case despite all previous randomized 
controlled trials (RCT) targeting patients with PD in an advanced phase.
Although istradefylline was known to block A2A receptors in the indirect pathway, the network-level mode 
of action for istradefylline has remained an enigma. Prior reports identified abnormal brain networks in PD28,29, 
for which the elucidation of the effect of istradefylline could lead to the development of novel adenosinergic 
therapies.
The previous meta-analysis reported significant effect of 40 mg/day istradefylline on reduction of off time with 
heterogeneous studies, but failed to demonstrate that 20 mg/day istradefylline could improve motor symptoms18. 
Additional studies and usage of standardized value allowed us to reveal significant effects of istradefylline with 
homogeneous studies. The assessment of a funnel plot revealed that summary effect of istradefylline on dyskine-
sia could be biased by publication. Moreover, the present research added new evidence of favorable tolerability.
This meta-analysis had multiple limitations. First, it was possible that limiting the search to studies written in 
English, and the modest number of included studies, might contribute to bias. Second, Egger’s test detected pub-
lication bias in the analysis of dyskinesia. Third, the included studies examined the short-term effect of istradefyl-
line on patients with PD. One open-label study showed the long-term effect of istradefylline30, but we require an 
RCT with long-term follow up to reveal the longitudinal outcome including the putative neuroprotective effect.
In summary, the present meta-analysis has provided robust evidence that istradefylline at 20 mg/day improves 
UPDRS III, and at 40 mg/day improves both off time and UPDRS III. The latter findings were further supported 
by sensitivity analyses. There was no significant difference in dropout ratio between istradefylline and placebo 
groups, which suggested this drug was well tolerated. However, dyskinesia could be worsened, but publication bias 
was detected, leaving the issue murky. Istradefylline at 40 mg/day is the only drug to have meta-analysis-based 
evidence among non-dopaminergic drugs potentially useful in PD, and is recommended for administration in 
the early phases of PD, or at least before the onset of motor complications.
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